XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 11.24%514.58M | 12.37%322.29M | 17.76%150.72M | 0.62%651.88M | -8.51%462.59M | -11.57%286.82M | -14.95%127.98M | 9.60%647.9M | 21.86%505.64M | 29.19%324.36M |
Operating revenue | 11.24%514.58M | 12.37%322.29M | 17.76%150.72M | 0.62%651.88M | -8.51%462.59M | -11.57%286.82M | -14.95%127.98M | 9.60%647.9M | 21.86%505.64M | 29.19%324.36M |
Other operating revenue | ---- | 27.59%5.3M | ---- | 49.34%11.6M | ---- | -15.30%4.16M | ---- | 10.88%7.77M | ---- | 180.38%4.91M |
Total operating cost | 13.50%419.38M | 11.97%261.83M | 2.41%115.83M | -2.38%527.9M | -11.80%369.5M | -13.55%233.84M | -11.82%113.1M | 7.99%540.78M | 19.56%418.91M | 23.92%270.48M |
Operating cost | 10.34%352.84M | 7.00%219.58M | 2.91%97.24M | -3.02%443.15M | -10.78%319.77M | -11.21%205.22M | -12.28%94.49M | 11.84%456.94M | 24.79%358.41M | 32.04%231.12M |
Operating tax surcharges | 5.92%4.9M | 0.82%3.16M | 23.60%1.7M | 19.69%5.83M | 27.49%4.62M | 68.52%3.14M | 362.49%1.37M | 37.49%4.87M | 19.16%3.63M | -22.03%1.86M |
Operating expense | -31.54%6.77M | 15.38%7.15M | -88.56%598.72K | -1.06%14.44M | -20.38%9.88M | -21.22%6.19M | -3.60%5.24M | 60.11%14.59M | 61.20%12.42M | 41.09%7.86M |
Administration expense | 37.49%37.53M | 37.90%23.97M | 111.63%13.71M | 4.14%45.65M | -11.50%27.3M | -8.41%17.39M | -23.46%6.48M | 2.89%43.84M | 7.85%30.85M | 1.26%18.98M |
Financial expense | 72.04%-2.92M | 46.34%-4.92M | -863.56%-3.24M | -10.25%-8.89M | -45.09%-10.43M | -189.32%-9.17M | -79.11%424.37K | -179.57%-8.07M | -225.67%-7.19M | -169.39%-3.17M |
-Interest expense (Financial expense) | 2,513.42%146.67K | 1,647.19%98.05K | ---- | -99.57%26K | -99.87%5.61K | -99.89%5.61K | -99.94%1.38K | -29.63%6.05M | -28.87%4.43M | 27.34%4.92M |
-Interest Income (Financial expense) | 14.12%-4.77M | -364.07%-2.56M | -655.24%-3.1M | -61.32%-5.06M | -365.20%-5.55M | 72.56%-552.36K | 34.22%-410.21K | -57.69%-3.14M | -225.28%-1.19M | -1,253.89%-2.01M |
Research and development | 10.38%20.25M | 16.30%12.88M | 14.32%5.83M | -3.10%27.72M | -11.81%18.35M | -19.85%11.08M | -19.54%5.1M | 6.65%28.6M | 14.85%20.8M | 15.57%13.82M |
Credit Impairment Loss | -3.12%-532.17K | -329.39%-247.15K | -328.63%-1.86M | -518.02%-3.09M | 24.00%-516.09K | 116.06%107.74K | 180.26%812.54K | -60.90%740.33K | 85.70%-679.06K | 80.19%-670.79K |
Asset Impairment Loss | ---- | ---- | ---- | -173.35%-11.1M | ---- | ---- | ---- | -15.26%-4.06M | ---- | ---- |
Other net revenue | 12.47%11.83M | 25.43%8.7M | -18.94%3.11M | -49.46%5.56M | -21.95%10.51M | -0.37%6.94M | 175.86%3.83M | -51.19%11.01M | 66.90%13.47M | 6.54%6.96M |
Fair value change income | -6.92%8.99M | 10.55%6.87M | 48.50%3.86M | 51.86%14.47M | 15.49%9.66M | 60.09%6.22M | --2.6M | -11.66%9.53M | 1,793.85%8.36M | 779.34%3.88M |
Invest income | ---- | ---- | ---- | -76.99%560.97K | -99.95%1.65K | ---- | ---- | -74.80%2.44M | -69.97%3.33M | -73.29%2.27M |
-Including: Investment income associates | ---- | ---- | ---- | ---145.16K | ---- | ---- | ---- | ---- | ---- | ---- |
Asset deal income | 533.18%35.82K | 72.65%25.78K | 48.75%6.97K | 46.83%298.53K | -97.15%5.66K | -92.64%14.93K | 114.13%4.68K | -54.89%203.32K | -54.12%198.3K | -51.70%202.84K |
Other revenue | 143.96%3.33M | 241.66%2.05M | 164.17%1.1M | 105.19%4.44M | -39.47%1.37M | -52.91%601.35K | -17.35%415.11K | -33.89%2.16M | 166.28%2.26M | 133.03%1.28M |
Operating profit | 3.30%107.03M | 15.43%69.17M | 102.99%38M | 9.67%129.55M | 3.40%103.61M | -1.51%59.93M | -20.75%18.72M | 4.60%118.12M | 37.99%100.2M | 54.71%60.84M |
Add:Non operating Income | -89.03%146.13K | -97.94%19.4K | -116.69%-51.86K | -6.00%1.73M | 9.90%1.33M | 0.59%943.96K | -52.26%310.77K | 13.31%1.84M | -0.27%1.21M | 2.73%938.44K |
Less:Non operating expense | 162.43%739.68K | 44,675.54%734.36K | 1,220.21%20.26K | 998.70%291.11K | 1,107.33%281.86K | -91.81%1.64K | -74.22%1.53K | -83.70%26.5K | -85.51%23.35K | -87.91%20.03K |
Total profit | 1.70%106.44M | 12.46%68.45M | 99.31%37.93M | 9.21%130.98M | 3.22%104.66M | -1.45%60.87M | -21.58%19.03M | 4.85%119.94M | 37.63%101.39M | 54.12%61.76M |
Less:Income tax cost | 14.90%13.44M | 34.70%9.7M | 124.33%5.03M | -34.48%10.6M | -2.66%11.69M | -19.89%7.2M | -33.02%2.24M | -12.33%16.18M | 8.55%12.01M | 37.92%8.99M |
Net profit | 0.04%93M | 9.48%58.75M | 95.97%32.89M | 16.03%120.38M | 4.02%92.96M | 1.69%53.66M | -19.75%16.78M | 8.16%103.75M | 42.77%89.38M | 57.27%52.77M |
Net profit from continuing operation | 0.04%93M | 9.48%58.75M | 95.97%32.89M | 16.03%120.38M | 4.02%92.96M | 1.69%53.66M | -19.75%16.78M | 8.16%103.75M | 42.77%89.38M | 50.54%52.77M |
Net profit of parent company owners | 0.04%93M | 9.48%58.75M | 95.97%32.89M | 16.03%120.38M | 4.02%92.96M | 1.69%53.66M | -19.75%16.78M | 8.16%103.75M | 42.77%89.38M | 57.27%52.77M |
Earning per share | ||||||||||
Basic earning per share | 0.00%0.91 | 9.62%0.57 | 100.00%0.32 | 9.35%1.17 | -4.21%0.91 | -7.14%0.52 | -27.27%0.16 | 4.90%1.07 | 41.79%0.95 | 55.56%0.56 |
Diluted earning per share | 12.35%0.91 | 23.91%0.57 | 128.57%0.32 | 13.59%1.17 | -10.99%0.81 | -16.36%0.46 | -33.33%0.14 | 3.00%1.03 | 37.88%0.91 | 52.78%0.55 |
Other composite income | ||||||||||
Total composite income | 0.04%93M | 9.48%58.75M | 95.97%32.89M | 16.03%120.38M | 4.02%92.96M | 1.69%53.66M | -19.75%16.78M | 8.16%103.75M | 42.77%89.38M | 57.27%52.77M |
Total composite income of parent company owners | 0.04%93M | 9.48%58.75M | 95.97%32.89M | 16.03%120.38M | 4.02%92.96M | 1.69%53.66M | -19.75%16.78M | 8.16%103.75M | 42.77%89.38M | 57.27%52.77M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
Auditor | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.